BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 35470785)

  • 1. Identification of potential bioactive natural compounds from Indonesian medicinal plants against 3-chymotrypsin-like protease (3CL
    Prasetyo WE; Purnomo H; Sadrini M; Wibowo FR; Firdaus M; Kusumaningsih T
    J Biomol Struct Dyn; 2023 Jul; 41(10):4467-4484. PubMed ID: 35470785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants -
    Shree P; Mishra P; Selvaraj C; Singh SK; Chaube R; Garg N; Tripathi YB
    J Biomol Struct Dyn; 2022 Jan; 40(1):190-203. PubMed ID: 32851919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Phytochemicals from Arabian Peninsula Medicinal Plants as Strong Binders to SARS-CoV-2 Proteases (3CL
    Saquib Q; Bakheit AH; Ahmed S; Ansari SM; Al-Salem AM; Al-Khedhairy AA
    Molecules; 2024 Feb; 29(5):. PubMed ID: 38474509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CL
    Gyebi GA; Ogunro OB; Adegunloye AP; Ogunyemi OM; Afolabi SO
    J Biomol Struct Dyn; 2021 Jun; 39(9):3396-3408. PubMed ID: 32367767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based virtual screening suggests inhibitors of 3-Chymotrypsin-Like Protease of SARS-CoV-2 from Vernonia amygdalina and Occinum gratissimum.
    Gyebi GA; Elfiky AA; Ogunyemi OM; Ibrahim IM; Adegunloye AP; Adebayo JO; Olaiya CO; Ocheje JO; Fabusiwa MM
    Comput Biol Med; 2021 Sep; 136():104671. PubMed ID: 34332348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of potential phytochemicals from
    Khan J; Sakib SA; Mahmud S; Khan Z; Islam MN; Sakib MA; Emran TB; Simal-Gandara J
    J Biomol Struct Dyn; 2022; 40(21):10741-10752. PubMed ID: 34278965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2.
    Abdizadeh R; Hadizadeh F; Abdizadeh T
    Mol Divers; 2022 Apr; 26(2):1053-1076. PubMed ID: 34213728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying the natural compound Catechin from tropical mangrove plants as a potential lead candidate against 3CL
    Jha RK; Khan RJ; Parthiban A; Singh E; Jain M; Amera GM; Singh RP; Ramachandran P; Ramachandran R; Sachithanandam V; Muthukumaran J; Singh AK
    J Biomol Struct Dyn; 2022; 40(24):13392-13411. PubMed ID: 34644249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of Natural Bisbenzylisoquinoline Analogs from the Library of Thai Traditional Plants as SARS-CoV-2 3CL
    Khamto N; Utama K; Tateing S; Sangthong P; Rithchumpon P; Cheechana N; Saiai A; Semakul N; Punyodom W; Meepowpan P
    J Chem Inf Model; 2023 Apr; 63(7):2104-2121. PubMed ID: 36647612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caffeine and caffeine-containing pharmaceuticals as promising inhibitors for 3-chymotrypsin-like protease of SARS-CoV-2.
    Elzupir AO
    J Biomol Struct Dyn; 2022 Mar; 40(5):2113-2120. PubMed ID: 33094705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fourteen immunomodulatory alkaloids and two prenylated phenylpropanoids with dual therapeutic approach for COVID-19: molecular docking and dynamics studies.
    Omar R; Abd El-Salam M; Elsbaey M; Hassan M
    J Biomol Struct Dyn; 2024 Mar; 42(5):2298-2315. PubMed ID: 37116054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2
    Khan SA; Zia K; Ashraf S; Uddin R; Ul-Haq Z
    J Biomol Struct Dyn; 2021 Apr; 39(7):2607-2616. PubMed ID: 32238094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of apigenin-based biflavonoid derivatives as potential therapeutic agents against viral protease (3CLpro) of SARS-CoV-2 via molecular docking, molecular dynamics and quantum mechanics studies.
    Abdizadeh R; Hadizadeh F; Abdizadeh T
    J Biomol Struct Dyn; 2023; 41(13):5915-5945. PubMed ID: 35848354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An
    Mishra B; Ballaney P; Saha G; Shinde A; Banerjee S; Thimmakondu VS; Aduri R
    J Biomol Struct Dyn; 2023 May; 41(8):3167-3186. PubMed ID: 35261325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding and inhibitory effect of ravidasvir on 3CL
    Bera K
    J Biomol Struct Dyn; 2022 Oct; 40(16):7303-7310. PubMed ID: 33682639
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Iype E; Pillai U J; Kumar I; Gaastra-Nedea SV; Subramanian R; Saha RN; Dutta M
    J Biomol Struct Dyn; 2022; 40(23):12800-12811. PubMed ID: 34550861
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Sharma A; Goyal S; Yadav AK; Kumar P; Gupta L
    J Biomol Struct Dyn; 2022 Jan; 40(1):86-100. PubMed ID: 32896226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening potential FDA-approved inhibitors of the SARS-CoV-2 major protease 3CL
    Liu WS; Li HG; Ding CH; Zhang HX; Wang RR; Li JQ
    Aging (Albany NY); 2021 Mar; 13(5):6258-6272. PubMed ID: 33678621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CL
    Alamri MA; Tahir Ul Qamar M; Mirza MU; Bhadane R; Alqahtani SM; Muneer I; Froeyen M; Salo-Ahen OMH
    J Biomol Struct Dyn; 2021 Aug; 39(13):4936-4948. PubMed ID: 32579061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proposing a fungal metabolite-flaviolin as a potential inhibitor of 3CL
    Rao P; Shukla A; Parmar P; Rawal RM; Patel BV; Saraf M; Goswami D
    J Biomol Struct Dyn; 2022 Jan; 40(1):348-360. PubMed ID: 32875950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.